{"transactions":[{"id":673032,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-28T16:27:50.000Z","date":"2026-08-28","kind":"exercise","planned":true,"acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":65181,"derivative":{"exercise_price":8.43,"expiration_date":"2029-11-19","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001764013-26-000103","document":"wk-form4_1787948868.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000103/wk-form4_1787948868.xml","form_type":"4"}},{"id":673031,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-28T16:27:50.000Z","date":"2026-08-28","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":43.27,"value":64905.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."}],"balance_after":116731,"source":{"system":"sec-edgar","filing":"0001764013-26-000103","document":"wk-form4_1787948868.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000103/wk-form4_1787948868.xml","form_type":"4"}},{"id":673030,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-28T16:27:50.000Z","date":"2026-08-28","kind":"exercise","planned":true,"acquired":true,"shares":1500,"price":8.43,"value":12645.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."}],"balance_after":118231,"source":{"system":"sec-edgar","filing":"0001764013-26-000103","document":"wk-form4_1787948868.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000103/wk-form4_1787948868.xml","form_type":"4"}},{"id":703533,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-24T21:59:12.000Z","date":"2026-07-24","kind":"exercise","planned":true,"acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":66681,"derivative":{"exercise_price":8.43,"expiration_date":"2029-11-19","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001643071-26-000007","document":"wk-form4_1784930349.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000164307126000007/wk-form4_1784930349.xml","form_type":"4"}},{"id":703532,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-24T21:59:12.000Z","date":"2026-07-24","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":39.8,"value":59700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."}],"balance_after":116731,"source":{"system":"sec-edgar","filing":"0001643071-26-000007","document":"wk-form4_1784930349.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000164307126000007/wk-form4_1784930349.xml","form_type":"4"}},{"id":703531,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-24T21:59:12.000Z","date":"2026-07-24","kind":"exercise","planned":true,"acquired":true,"shares":1500,"price":8.43,"value":12645.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."}],"balance_after":118231,"source":{"system":"sec-edgar","filing":"0001643071-26-000007","document":"wk-form4_1784930349.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000164307126000007/wk-form4_1784930349.xml","form_type":"4"}},{"id":725536,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T23:43:23.000Z","date":"2026-06-26","kind":"exercise","planned":true,"acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":68181,"derivative":{"exercise_price":8.43,"expiration_date":"2029-11-19","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001764013-26-000071","document":"wk-form4_1782517401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000071/wk-form4_1782517401.xml","form_type":"4"}},{"id":725535,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T23:43:23.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":38.01,"value":57015.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."}],"balance_after":116731,"source":{"system":"sec-edgar","filing":"0001764013-26-000071","document":"wk-form4_1782517401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000071/wk-form4_1782517401.xml","form_type":"4"}},{"id":725534,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T23:43:23.000Z","date":"2026-06-26","kind":"exercise","planned":true,"acquired":true,"shares":1500,"price":8.43,"value":12645.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."}],"balance_after":118231,"source":{"system":"sec-edgar","filing":"0001764013-26-000071","document":"wk-form4_1782517401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000071/wk-form4_1782517401.xml","form_type":"4"}},{"id":736245,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-16T20:03:13.000Z","date":"2026-06-15","kind":"exercise","planned":true,"acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Form 4 filed on May 20, 2026 inadvertently disclosed the total of all remaining options held by the Reporting Person following the reported transaction in this specific option. This total correctly reflects only the remaining options for the specific option."}],"balance_after":69681,"derivative":{"exercise_price":8.43,"expiration_date":"2029-11-19","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001764013-26-000069","document":"wk-form4_1781640191.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000069/wk-form4_1781640191.xml","form_type":"4"}},{"id":736244,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T20:03:13.000Z","date":"2026-06-15","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":34.02,"value":51030.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."}],"balance_after":116731,"source":{"system":"sec-edgar","filing":"0001764013-26-000069","document":"wk-form4_1781640191.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000069/wk-form4_1781640191.xml","form_type":"4"}},{"id":736243,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T20:03:13.000Z","date":"2026-06-15","kind":"exercise","planned":true,"acquired":true,"shares":1500,"price":8.43,"value":12645.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."}],"balance_after":118231,"source":{"system":"sec-edgar","filing":"0001764013-26-000069","document":"wk-form4_1781640191.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000069/wk-form4_1781640191.xml","form_type":"4"}},{"id":770074,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-21T01:22:04.000Z","date":"2026-05-20","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":270252,"derivative":{"exercise_price":8.43,"expiration_date":"2029-11-19","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001643071-26-000004","document":"wk-form4_1779326521.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000164307126000004/wk-form4_1779326521.xml","form_type":"4"}},{"id":770073,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T01:22:04.000Z","date":"2026-05-20","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":32,"value":192000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."}],"balance_after":116731,"source":{"system":"sec-edgar","filing":"0001643071-26-000004","document":"wk-form4_1779326521.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000164307126000004/wk-form4_1779326521.xml","form_type":"4"}},{"id":770072,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T01:22:04.000Z","date":"2026-05-20","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":8.43,"value":50580.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."}],"balance_after":122731,"source":{"system":"sec-edgar","filing":"0001643071-26-000004","document":"wk-form4_1779326521.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000164307126000004/wk-form4_1779326521.xml","form_type":"4"}},{"id":811522,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-09T20:25:16.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":7061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":7061,"derivative":{"exercise_price":24.61,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":7061},"source":{"system":"sec-edgar","filing":"0001764013-26-000046","document":"wk-form4_1775766313.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000046/wk-form4_1775766313.xml","form_type":"4"}},{"id":811521,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T20:25:16.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":13880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units (\"RSUs\") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the \"Plan\"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."}],"balance_after":116731,"source":{"system":"sec-edgar","filing":"0001764013-26-000046","document":"wk-form4_1775766313.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000046/wk-form4_1775766313.xml","form_type":"4"}},{"id":1179759,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-03T20:44:34.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":7600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the options will vest on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":7600,"derivative":{"exercise_price":15.2,"expiration_date":"2035-04-01","underlying":"Common Stock","underlying_shares":7600},"source":{"system":"sec-edgar","filing":"0001764013-25-000047","document":"wk-form4_1743713068.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000047/wk-form4_1743713068.xml","form_type":"4"}},{"id":1179758,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-03T20:44:34.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":16188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units (\"RSUs\") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."}],"balance_after":102851,"source":{"system":"sec-edgar","filing":"0001764013-25-000047","document":"wk-form4_1743713068.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000047/wk-form4_1743713068.xml","form_type":"4"}},{"id":1343076,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-04T21:22:39.000Z","date":"2024-12-02","kind":"sale","planned":true,"acquired":false,"shares":7750,"price":28.54,"value":221185.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 24, 2023 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.03 - $29.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":86663,"source":{"system":"sec-edgar","filing":"0001764013-24-000200","document":"wk-form4_1733347352.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000200/wk-form4_1733347352.xml","form_type":"4"}},{"id":1547841,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-04T20:46:09.000Z","date":"2024-04-02","kind":"grant","planned":false,"acquired":true,"shares":4690,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the options will vest on April 2, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":4690,"derivative":{"exercise_price":30.78,"expiration_date":"2034-04-02","underlying":"Common Stock","underlying_shares":4690},"source":{"system":"sec-edgar","filing":"0001764013-24-000061","document":"wk-form4_1712263559.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000061/wk-form4_1712263559.xml","form_type":"4"}},{"id":1547840,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T20:46:09.000Z","date":"2024-04-02","kind":"grant","planned":false,"acquired":true,"shares":11255,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units (\"RSUs\") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 2, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."}],"balance_after":94413,"source":{"system":"sec-edgar","filing":"0001764013-24-000061","document":"wk-form4_1712263559.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000061/wk-form4_1712263559.xml","form_type":"4"}},{"id":1572326,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:57.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1904,"price":92.3,"value":175739.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date."}],"balance_after":0,"derivative":{"exercise_price":237.7,"expiration_date":"2033-06-19","underlying":"Common Stock","underlying_shares":1904},"source":{"system":"sec-edgar","filing":"0001140361-24-013932","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000114036124013932/form4.xml","form_type":"4"}},{"id":1572325,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:57.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5000,"price":227.04,"value":1135200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":102.96,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001140361-24-013932","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000114036124013932/form4.xml","form_type":"4"}},{"id":1572324,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:57.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8500,"price":201.99,"value":1716915.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":128.01,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001140361-24-013932","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000114036124013932/form4.xml","form_type":"4"}},{"id":1572323,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:57.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"price":232.41,"value":2905125.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":97.59,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001140361-24-013932","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000114036124013932/form4.xml","form_type":"4"}},{"id":1572322,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-18T20:30:57.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":990,"price":330,"value":326700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-013932","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000114036124013932/form4.xml","form_type":"4"}},{"id":1721890,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-05T21:28:23.000Z","date":"2023-12-01","kind":"sale","planned":true,"acquired":false,"shares":4847,"price":40.46,"value":196109.62,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan adopted on May 24, 2023, in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the above award of restricted stock covering shares of common stock and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40.23 - $40.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":83158,"source":{"system":"sec-edgar","filing":"0001764013-23-000155","document":"wk-form4_1701811692.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000155/wk-form4_1701811692.xml","form_type":"4"}},{"id":1721889,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-05T21:28:23.000Z","date":"2023-12-01","kind":"sale","planned":true,"acquired":false,"shares":3374,"price":39.82,"value":134352.68,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan adopted on May 24, 2023, in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the above award of restricted stock covering shares of common stock and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $39.21 - $40.17 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":88005,"source":{"system":"sec-edgar","filing":"0001764013-23-000155","document":"wk-form4_1701811692.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000155/wk-form4_1701811692.xml","form_type":"4"}},{"id":1721888,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-05T21:28:23.000Z","date":"2023-12-01","kind":"sale","planned":true,"acquired":false,"shares":4129,"price":38.8,"value":160205.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan adopted on May 24, 2023, in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the above award of restricted stock covering shares of common stock and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.20 - $39.17 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":91379,"source":{"system":"sec-edgar","filing":"0001764013-23-000155","document":"wk-form4_1701811692.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000155/wk-form4_1701811692.xml","form_type":"4"}},{"id":1846502,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2023-06-22T20:09:40.000Z","date":"2023-06-20","kind":"grant","planned":false,"acquired":true,"shares":1904,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest in full upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such dates."}],"balance_after":1904,"derivative":{"exercise_price":237.7,"expiration_date":"2033-06-19","underlying":"Common Stock","underlying_shares":1904},"source":{"system":"sec-edgar","filing":"0000950170-23-029403","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000095017023029403/ownership.xml","form_type":"4"}},{"id":1846501,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-22T20:09:40.000Z","date":"2023-06-20","kind":"grant","planned":false,"acquired":true,"shares":990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Comprised of restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in full upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such dates."}],"balance_after":990,"source":{"system":"sec-edgar","filing":"0000950170-23-029403","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000095017023029403/ownership.xml","form_type":"4"}},{"id":1919639,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-04-14T20:37:22.000Z","date":"2023-04-12","kind":"grant","planned":false,"acquired":true,"shares":16260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the options vest one year after the date of grant on April 12, 2024, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":16260,"derivative":{"exercise_price":14.7,"expiration_date":"2033-04-12","underlying":"Common Stock","underlying_shares":16260},"source":{"system":"sec-edgar","filing":"0001764013-23-000047","document":"wf-form4_168150462958764.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000047/wf-form4_168150462958764.xml","form_type":"4"}},{"id":1919638,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-14T20:37:22.000Z","date":"2023-04-12","kind":"grant","planned":false,"acquired":true,"shares":12523,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the number of shares underlying restricted stock units awards (\"RSUs\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs vest in their entirety one year after the date of grant on April 12, 2024, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."}],"balance_after":95508,"source":{"system":"sec-edgar","filing":"0001764013-23-000047","document":"wf-form4_168150462958764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000047/wf-form4_168150462958764.xml","form_type":"4"}},{"id":2144839,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-04T20:27:14.000Z","date":"2022-09-30","kind":"purchase","acquired":true,"shares":15000,"price":5.6,"value":84000.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.59 - $5.61 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned by a trust (the \"Trust\"). Certain members of the Reporting Person's immediate family are beneficiaries of the Trust."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001764013-22-000126","document":"wf-form4_166491518472332.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000126/wf-form4_166491518472332.xml","form_type":"4"}},{"id":2178367,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-08-19T20:46:09.000Z","date":"2022-08-17","kind":"grant","acquired":true,"shares":31668,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the options vest one year after the date of grant on August 17, 2023, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":31668,"derivative":{"exercise_price":4.99,"expiration_date":"2032-08-17","underlying":"Common Stock","underlying_shares":31668},"source":{"system":"sec-edgar","filing":"0001764013-22-000095","document":"wf-form4_166094195240810.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000095/wf-form4_166094195240810.xml","form_type":"4"}},{"id":2178366,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-19T20:46:09.000Z","date":"2022-08-17","kind":"grant","acquired":true,"shares":21059,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the number of shares underlying restricted stock units awards (\"RSUs\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs vest in their entirety one year after the date of grant on August 17, 2023, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."}],"balance_after":82985,"source":{"system":"sec-edgar","filing":"0001764013-22-000095","document":"wf-form4_166094195240810.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000095/wf-form4_166094195240810.xml","form_type":"4"}},{"id":2229935,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2022-06-16T20:39:12.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 15, 2023, and (ii) the 2023 annual meeting of the Issuer's stockholders."}],"balance_after":5000,"derivative":{"exercise_price":102.96,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001593968-22-001149","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396822001149/primary_01.xml","form_type":"4"}},{"id":2416649,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2022-02-02T21:08:56.000Z","date":"2022-02-01","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":16,"exercise_date":"2020-06-15","expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001593968-22-000362","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396822000362/primary_01.xml","form_type":"4"}},{"id":2416648,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-02T21:08:56.000Z","date":"2022-02-01","kind":"sale","acquired":false,"shares":2500,"price":110.8,"value":277000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001593968-22-000362","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396822000362/primary_01.xml","form_type":"4"}},{"id":2416647,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-02T21:08:56.000Z","date":"2022-02-01","kind":"exercise","acquired":true,"shares":2500,"price":16,"value":40000.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001593968-22-000362","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396822000362/primary_01.xml","form_type":"4"}},{"id":2436889,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-12T21:56:20.000Z","date":"2022-01-10","kind":"grant","acquired":true,"shares":71492,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Shares underlying the options vest over a period of two years, in a series of eight successive equal installments from the date of the award, subject to the Reporting Person providing continuous service to the Issuer as of each such date."}],"balance_after":208973,"derivative":{"exercise_price":7.94,"expiration_date":"2032-01-10","underlying":"Common Stock","underlying_shares":71492},"source":{"system":"sec-edgar","filing":"0001764013-22-000015","document":"wf-form4_164202456711747.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000015/wf-form4_164202456711747.xml","form_type":"4"}},{"id":2436888,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-12T21:56:20.000Z","date":"2022-01-10","kind":"grant","acquired":true,"shares":21726,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the number of shares underlying restricted stock units awards (\"RSUs\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs vest over a period of two years, in a series of eight successive equal installments from the date of the award, subject to the Reporting Person providing continuous service to the Issuer as of each such date."}],"balance_after":61926,"source":{"system":"sec-edgar","filing":"0001764013-22-000015","document":"wf-form4_164202456711747.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000015/wf-form4_164202456711747.xml","form_type":"4"}},{"id":2454303,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2022-01-04T00:05:48.000Z","date":"2022-01-03","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2500,"derivative":{"exercise_price":16,"exercise_date":"2020-06-15","expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001593968-22-000017","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396822000017/primary_01.xml","form_type":"4"}},{"id":2454302,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-04T00:05:48.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":2500,"price":130.44,"value":326100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001593968-22-000017","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396822000017/primary_01.xml","form_type":"4"}},{"id":2454301,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-04T00:05:48.000Z","date":"2022-01-03","kind":"exercise","acquired":true,"shares":2500,"price":16,"value":40000.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001593968-22-000017","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396822000017/primary_01.xml","form_type":"4"}},{"id":2488730,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-12-02T22:21:16.000Z","date":"2021-12-01","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5000,"derivative":{"exercise_price":16,"exercise_date":"2020-06-15","expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001593968-21-002517","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821002517/primary_01.xml","form_type":"4"}},{"id":2488729,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T22:21:16.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":2500,"price":127.73,"value":319325.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001593968-21-002517","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821002517/primary_01.xml","form_type":"4"}},{"id":2488728,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T22:21:16.000Z","date":"2021-12-01","kind":"exercise","acquired":true,"shares":2500,"price":16,"value":40000.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001593968-21-002517","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821002517/primary_01.xml","form_type":"4"}},{"id":2526314,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-11-03T20:14:06.000Z","date":"2021-11-01","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7500,"derivative":{"exercise_price":16,"exercise_date":"2020-06-15","expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001593968-21-002355","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821002355/primary_01.xml","form_type":"4"}},{"id":2526313,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T20:14:06.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":2500,"price":136.67,"value":341675.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001593968-21-002355","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821002355/primary_01.xml","form_type":"4"}},{"id":2526312,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T20:14:06.000Z","date":"2021-11-01","kind":"exercise","acquired":true,"shares":2500,"price":16,"value":40000.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001593968-21-002355","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821002355/primary_01.xml","form_type":"4"}},{"id":2554404,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-10-01T20:21:54.000Z","date":"2021-10-01","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10000,"derivative":{"exercise_price":16,"exercise_date":"2020-06-15","expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001593968-21-002217","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821002217/primary_01.xml","form_type":"4"}},{"id":2554403,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-01T20:21:54.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":2500,"price":120.72,"value":301800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001593968-21-002217","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821002217/primary_01.xml","form_type":"4"}},{"id":2554402,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-01T20:21:54.000Z","date":"2021-10-01","kind":"exercise","acquired":true,"shares":2500,"price":16,"value":40000.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001593968-21-002217","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821002217/primary_01.xml","form_type":"4"}},{"id":2583539,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-09-01T20:28:04.000Z","date":"2021-09-01","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12500,"derivative":{"exercise_price":16,"exercise_date":"2020-06-15","expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001593968-21-002050","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821002050/primary_01.xml","form_type":"4"}},{"id":2583538,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-01T20:28:04.000Z","date":"2021-09-01","kind":"sale","acquired":false,"shares":2500,"price":117.82,"value":294550.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001593968-21-002050","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821002050/primary_01.xml","form_type":"4"}},{"id":2583537,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-01T20:28:04.000Z","date":"2021-09-01","kind":"exercise","acquired":true,"shares":2500,"price":16,"value":40000.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001593968-21-002050","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821002050/primary_01.xml","form_type":"4"}},{"id":2602386,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-16T21:29:22.000Z","date":"2021-08-13","kind":"purchase","acquired":true,"shares":5000,"price":7.98,"value":39900.0,"ownership":{"direct":false,"nature":"Purchased through Trust Owned by Atul Pande and his Spouse"},"balance_after":45200,"source":{"system":"sec-edgar","filing":"0001764013-21-000088","document":"wf-form4_162914934479727.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401321000088/wf-form4_162914934479727.xml","form_type":"4"}},{"id":2620016,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-08-02T20:49:38.000Z","date":"2021-08-02","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15000,"derivative":{"exercise_price":16,"exercise_date":"2020-06-15","expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001593968-21-001919","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821001919/primary_01.xml","form_type":"4"}},{"id":2620015,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-02T20:49:38.000Z","date":"2021-08-02","kind":"sale","acquired":false,"shares":2500,"price":114.17,"value":285425.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001593968-21-001919","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821001919/primary_01.xml","form_type":"4"}},{"id":2620014,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-02T20:49:38.000Z","date":"2021-08-02","kind":"exercise","acquired":true,"shares":2500,"price":16,"value":40000.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001593968-21-001919","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821001919/primary_01.xml","form_type":"4"}},{"id":2647573,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-07-01T20:19:17.000Z","date":"2021-07-01","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":17500,"derivative":{"exercise_price":16,"exercise_date":"2020-06-15","expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001593968-21-001740","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821001740/primary_01.xml","form_type":"4"}},{"id":2647572,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-01T20:19:17.000Z","date":"2021-07-01","kind":"sale","acquired":false,"shares":2500,"price":112.66,"value":281650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001593968-21-001740","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821001740/primary_01.xml","form_type":"4"}},{"id":2647571,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-01T20:19:17.000Z","date":"2021-07-01","kind":"exercise","acquired":true,"shares":2500,"price":16,"value":40000.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001593968-21-001740","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821001740/primary_01.xml","form_type":"4"}},{"id":2657082,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-06-23T20:35:46.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 16, 2022, and (ii) the 2022 annual meeting of the Issuer's stockholders."}],"balance_after":8500,"derivative":{"exercise_price":128.01,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001593968-21-001685","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821001685/primary_01.xml","form_type":"4"}},{"id":2688971,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-06-01T20:45:48.000Z","date":"2021-06-01","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20000,"derivative":{"exercise_price":16,"exercise_date":"2020-06-27","expiration_date":"2029-06-27","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001593968-21-001490","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821001490/primary_01.xml","form_type":"4"}},{"id":2688970,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-01T20:45:48.000Z","date":"2021-06-01","kind":"sale","acquired":false,"shares":2500,"price":111.44,"value":278600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001593968-21-001490","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821001490/primary_01.xml","form_type":"4"}},{"id":2688969,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-01T20:45:48.000Z","date":"2021-06-01","kind":"exercise","acquired":true,"shares":2500,"price":16,"value":40000.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001593968-21-001490","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821001490/primary_01.xml","form_type":"4"}},{"id":2733020,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-05-03T21:10:58.000Z","date":"2021-05-03","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22500,"derivative":{"exercise_price":16,"exercise_date":"2020-06-27","expiration_date":"2029-06-27","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001593968-21-001217","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821001217/primary_01.xml","form_type":"4"}},{"id":2733019,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-05-03T21:10:58.000Z","date":"2021-04-01","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":16,"exercise_date":"2020-06-27","expiration_date":"2029-06-27","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001593968-21-001217","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821001217/primary_01.xml","form_type":"4"}},{"id":2733018,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-03T21:10:58.000Z","date":"2021-05-03","kind":"sale","acquired":false,"shares":2500,"price":110.61,"value":276525.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001593968-21-001217","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821001217/primary_01.xml","form_type":"4"}},{"id":2733017,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-03T21:10:58.000Z","date":"2021-05-03","kind":"exercise","acquired":true,"shares":2500,"price":16,"value":40000.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001593968-21-001217","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821001217/primary_01.xml","form_type":"4"}},{"id":2733016,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-03T21:10:58.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":2500,"price":120.01,"value":300025.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001593968-21-001217","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821001217/primary_01.xml","form_type":"4"}},{"id":2733015,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-03T21:10:58.000Z","date":"2021-04-01","kind":"exercise","acquired":true,"shares":2500,"price":16,"value":40000.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001593968-21-001217","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821001217/primary_01.xml","form_type":"4"}},{"id":2745114,"issuer":{"id":130622,"kind":"organization","name":"Sio Gene Therapies Inc.","symbol":"SIOX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-19T20:55:29.000Z","date":"2021-04-15","kind":"grant","acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of this option will vest on April 15, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan."}],"balance_after":42000,"derivative":{"exercise_price":2.47,"expiration_date":"2031-04-14","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001636050-21-000048","document":"wf-form4_161886571482336.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000163605021000048/wf-form4_161886571482336.xml","form_type":"4"}},{"id":2775016,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-03-23T12:53:27.000Z","date":"2021-03-19","kind":"grant","acquired":true,"shares":23300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the options vest one year after the date of grant on March 19, 2022, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":23300,"derivative":{"exercise_price":17,"expiration_date":"2031-03-19","underlying":"Common Stock","underlying_shares":23300},"source":{"system":"sec-edgar","filing":"0001764013-21-000043","document":"wf-form4_161650399568493.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401321000043/wf-form4_161650399568493.xml","form_type":"4"}},{"id":2775015,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-23T12:53:27.000Z","date":"2021-03-19","kind":"grant","acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares underlying restricted stock unit awards (\"RSUs\") granted to the Reporting Person pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in their entirety one year after the date of grant on March 19, 2022, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."}],"balance_after":40200,"source":{"system":"sec-edgar","filing":"0001764013-21-000043","document":"wf-form4_161650399568493.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401321000043/wf-form4_161650399568493.xml","form_type":"4"}},{"id":2813556,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-03-03T21:19:04.000Z","date":"2021-03-01","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":27500,"derivative":{"exercise_price":16,"exercise_date":"2020-06-27","expiration_date":"2029-06-27","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001593968-21-000765","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821000765/primary_01.xml","form_type":"4"}},{"id":2813555,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-03T21:19:04.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":2500,"price":125.43,"value":313575.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001593968-21-000765","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821000765/primary_01.xml","form_type":"4"}},{"id":2813554,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-03T21:19:04.000Z","date":"2021-03-01","kind":"exercise","acquired":true,"shares":2500,"price":16,"value":40000.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001593968-21-000765","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821000765/primary_01.xml","form_type":"4"}},{"id":2888637,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-02-01T21:23:40.000Z","date":"2021-02-01","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":30000,"derivative":{"exercise_price":16,"exercise_date":"2020-06-27","expiration_date":"2029-06-27","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001593968-21-000271","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821000271/primary_01.xml","form_type":"4"}},{"id":2888636,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-01T21:23:40.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":2500,"price":100,"value":250000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001593968-21-000271","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821000271/primary_01.xml","form_type":"4"}},{"id":2888635,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-01T21:23:40.000Z","date":"2021-02-01","kind":"exercise","acquired":true,"shares":2500,"price":16,"value":40000.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001593968-21-000271","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396821000271/primary_01.xml","form_type":"4"}},{"id":2946616,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2020-12-14T22:10:31.000Z","date":"2020-12-14","kind":"exercise","acquired":false,"shares":5714,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":2.92,"exercise_date":"2016-05-31","expiration_date":"2026-05-31","underlying":"Common Stock","underlying_shares":5714},"source":{"system":"sec-edgar","filing":"0001593968-20-002354","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396820002354/primary_01.xml","form_type":"4"}},{"id":2946615,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-14T22:10:31.000Z","date":"2020-12-14","kind":"sale","acquired":false,"shares":5714,"price":92.64,"value":529344.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001593968-20-002354","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396820002354/primary_01.xml","form_type":"4"}},{"id":2946614,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-14T22:10:31.000Z","date":"2020-12-14","kind":"exercise","acquired":true,"shares":5714,"price":2.92,"value":16684.88,"ownership":{"direct":true},"balance_after":5714,"source":{"system":"sec-edgar","filing":"0001593968-20-002354","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396820002354/primary_01.xml","form_type":"4"}},{"id":2966192,"issuer":{"id":130622,"kind":"organization","name":"Sio Gene Therapies Inc.","symbol":"SIOX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-26T02:07:03.000Z","date":"2020-11-24","kind":"purchase","acquired":true,"shares":10000,"price":2.3399,"value":23399.0,"ownership":{"direct":false,"nature":"By Atul C. Pande and Patricia A Pande TR DTD 08/24/2017"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.33 to $2.34 per share, inclusive. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchase at each separate price within the range set forth in this footnote."}],"balance_after":33370,"source":{"system":"sec-edgar","filing":"0001636050-20-000105","document":"wf-form4_160635640441285.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000163605020000105/wf-form4_160635640441285.xml","form_type":"4"}},{"id":2983640,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2020-11-12T21:23:43.000Z","date":"2020-11-12","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5714,"derivative":{"exercise_price":2.92,"exercise_date":"2016-05-31","expiration_date":"2026-05-31","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001593968-20-002188","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396820002188/primary_01.xml","form_type":"4"}},{"id":2983639,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-12T21:23:43.000Z","date":"2020-11-12","kind":"sale","acquired":false,"shares":5000,"price":96.84,"value":484200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001593968-20-002188","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396820002188/primary_01.xml","form_type":"4"}},{"id":2983638,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-12T21:23:43.000Z","date":"2020-11-12","kind":"exercise","acquired":true,"shares":5000,"price":2.92,"value":14600.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001593968-20-002188","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396820002188/primary_01.xml","form_type":"4"}},{"id":2994838,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2020-11-03T21:44:57.000Z","date":"2020-11-03","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10714,"derivative":{"exercise_price":2.92,"exercise_date":"2016-05-31","expiration_date":"2026-05-31","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001593968-20-002123","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396820002123/primary_01.xml","form_type":"4"}},{"id":2994837,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-03T21:44:57.000Z","date":"2020-11-03","kind":"sale","acquired":false,"shares":5000,"price":85,"value":425000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001593968-20-002123","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396820002123/primary_01.xml","form_type":"4"}},{"id":2994836,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-03T21:44:57.000Z","date":"2020-11-03","kind":"exercise","acquired":true,"shares":5000,"price":2.92,"value":14600.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001593968-20-002123","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396820002123/primary_01.xml","form_type":"4"}},{"id":3026991,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2020-09-18T20:09:27.000Z","date":"2020-09-16","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15714,"derivative":{"exercise_price":2.92,"exercise_date":"2016-05-31","expiration_date":"2026-05-31","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001593968-20-001897","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396820001897/primary_01.xml","form_type":"4"}},{"id":3026990,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-18T20:09:27.000Z","date":"2020-09-16","kind":"sale","acquired":false,"shares":5000,"price":85,"value":425000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001593968-20-001897","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396820001897/primary_01.xml","form_type":"4"}},{"id":3026989,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-18T20:09:27.000Z","date":"2020-09-16","kind":"exercise","acquired":true,"shares":5000,"price":2.92,"value":14600.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001593968-20-001897","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396820001897/primary_01.xml","form_type":"4"}},{"id":3057307,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2020-08-14T20:19:26.000Z","date":"2020-08-12","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20714,"derivative":{"exercise_price":2.92,"exercise_date":"2016-05-31","expiration_date":"2026-05-31","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001593968-20-001752","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396820001752/primary_01.xml","form_type":"4"}},{"id":3057306,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-14T20:19:26.000Z","date":"2020-08-12","kind":"sale","acquired":false,"shares":5000,"price":85,"value":425000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001593968-20-001752","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396820001752/primary_01.xml","form_type":"4"}},{"id":3057305,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-14T20:19:26.000Z","date":"2020-08-12","kind":"exercise","acquired":true,"shares":5000,"price":2.92,"value":14600.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001593968-20-001752","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643071/000159396820001752/primary_01.xml","form_type":"4"}}],"next_cursor":"2020-08-14T20:19:26.000000Z,3057305"}